| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Published online before print April 26, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
From (OSI) Eyetech, Incorporated, Lexington, Massachusetts
@ To whom correspondence should be addressed. E-mail: davesfenestra{at}yahoo.com.
 |
Abstract |
|---|
Vascular endothelial growth factor-A (VEGF-A) has recently been recognized as an important neuroprotectant in the central nervous system. Given its position as an anti-angiogenic target in the treatment of human diseases, understanding the extent of VEGF's role in neural cell survival is paramount. Here, we used a model of ischemia-reperfusion injury and found that VEGF-A exposure resulted in a dose-dependent reduction in retinal neuron apoptosis. Although mechanistic studies suggested that VEGF-A-induced volumetric blood flow to the retina may be partially responsible for the neuroprotection, ex vivo retinal culture demonstrated a direct neuroprotective effect for VEGF-A. VEGF receptor-2 (VEGFR2) expression was detected in several neuronal cell layers of the retina, and functional analyses showed that VEGFR2 was involved in retinal neuroprotection. VEGF-A was also shown to be involved in the adaptive response to retinal ischemia. Ischemic preconditioning 24 hours before ischemia-reperfusion injury increased VEGF-A levels and substantially decreased the number of apoptotic retinal cells. The protective effect of ischemic preconditioning was reversed after VEGF-A inhibition. Finally, chronic inhibition of VEGF-A function in normal adult animals led to a significant loss of retinal ganglion cells yet had no observable effect on several vascular parameters. These findings have implications for both neural pathologies and ocular vascular diseases, such as diabetic retinopathy and age-related macular degeneration.
This article has been cited by other articles:
 |
|
 |
|
  L J Singerman, H Masonson, M Patel, A P Adamis, R Buggage, E Cunningham, M Goldbaum, B Katz, and D Guyer Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br. J. Ophthalmol., December 1, 2008; 92(12): 1606 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lange, Y. Yafai, A. Reichenbach, P. Wiedemann, and W. Eichler Regulation of Pigment Epithelium-Derived Factor Production and Release by Retinal Glial (Muller) Cells under Hypoxia Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5161 - 5167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Franco, D. C. Fernandez, P. H. Sande, M. I. Keller Sarmiento, M. Chianelli, D. A. Saenz, and R. E. Rosenstein Effect of Bacterial Lipopolysaccharide on Ischemic Damage in the Rat Retina Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4604 - 4612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Q. Yu, M. Zhang, K. I. Matis, C. Kim, and M. I. Rosenblatt Vascular Endothelial Growth Factor Mediates Corneal Nerve Repair Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3870 - 3878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Salom, M. Diaz-Llopis, S. Garcia-Delpech, P. Udaondo, M. Sancho-Tello, and F. J. Romero Aqueous Humor Levels of Vascular Endothelial Growth Factor in Retinitis Pigmentosa Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3499 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kong, H. A. Mintz-Hittner, R. L. Penland, F. L. Kretzer, and P. Chevez-Barrios Intravitreous Bevacizumab as Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study Arch Ophthalmol, August 1, 2008; 126(8): 1161 - 1163. [Full Text] [PDF]
|
|
|
|
|
|
P C. Issa, R P Finger, F G Holz, and H P N Scholl Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia Br. J. Ophthalmol., July 1, 2008; 92(7): 941 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, M. G. Mameza, Y. S. Lee, C. I. Eseonu, C.-R. Yu, J. J. Kang Derwent, and C. E. Egwuagu Suppressors of Cytokine-Signaling Proteins Induce Insulin Resistance in the Retina and Promote Survival of Retinal Cells Diabetes, June 1, 2008; 57(6): 1651 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Marko and D. H. Damon VEGF promotes vascular sympathetic innervation Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2646 - H2652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Taoufik, E. Petit, D. Divoux, V. Tseveleki, M. Mengozzi, M. L. Roberts, S. Valable, P. Ghezzi, J. Quackenbush, M. Brines, et al. TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injury PNAS, April 22, 2008; 105(16): 6185 - 6190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Ali, S. Matragoon, B. A. Pillai, G. I. Liou, and A. B. El-Remessy Peroxynitrite Mediates Retinal Neurodegeneration by Inhibiting Nerve Growth Factor Survival Signaling in Experimental and Human Diabetes Diabetes, April 1, 2008; 57(4): 889 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Bryan, T. E. Walshe, D. C. Mitchell, J. S. Havumaki, M. Saint-Geniez, A. S. Maharaj, A. E. Maldonado, and P. A. D'Amore Coordinated Vascular Endothelial Growth Factor Expression and Signaling During Skeletal Myogenic Differentiation Mol. Biol. Cell, March 1, 2008; 19(3): 994 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Im and A. Kazlauskas Src Family Kinases Promote Vessel Stability by Antagonizing the Rho/ROCK Pathway J. Biol. Chem., October 5, 2007; 282(40): 29122 - 29129. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
